For more than 50 years, the U.S. has led the world in government-funded cancer research. Since President Richard Nixon declared a national “war on cancer” in 1971, that investment has produced steady progress: new treatments, earlier detection methods, and improved survival rates. Today, nearly 70% of patients diagnosed with cancer live at least five years after their diagnosis — a major leap from just under 50% in the 1970s.
But experts warn that recent federal funding cuts and policy changes are putting this progress at risk, raising fears about the future of cancer research in the United States.
A Record of Progress
The nation’s cancer-research system stretches across universities, hospitals, and laboratories nationwide, and it has long been considered one of America’s greatest public-health achievements. By some estimates, every $326 invested in research extends a human life by one year.
Recent breakthroughs — including promising cancer vaccines and “flash” radiation that reduces damage to healthy tissue — highlight how decades of investment are paying off. Researchers say we are now closer than ever to transformative advances in how cancer is prevented, detected, and treated.
Policy Shifts and Budget Cuts
Unlike past administrations, which tried to maintain continuity at the National Institutes of Health (NIH) to avoid disrupting ongoing work, the Trump administration moved to reduce funding sharply.
Cuts to research grants and contracts: Hundreds of millions of dollars in cancer-related projects have been canceled, delayed, or left unfunded.
National Cancer Institute (NCI) budget reductions: Proposals sought to slash its funding by more than one-third.
Overhead changes: Plans to reduce reimbursement for lab operating expenses created new financial strain for universities.
Political appointments: The number of political appointees within NIH grew from just two positions to more than 20, reshaping how decisions were made.
Researchers say these disruptions are already slowing progress, as many projects rely on consistent multi-year funding to succeed.
The Vulnerability of the System
America’s cancer-research model is built on collaboration and long-term investment rather than short-term profit. Unlike Silicon Valley’s fast-moving innovation culture, biomedical research advances gradually, through shared knowledge and incremental discoveries.
That strength also makes it fragile. Once a trial is interrupted or a lab is forced to scale down, restarting the work is often costly and sometimes impossible.
The Human Impact
At the University of Massachusetts Chan Medical School, Dr. Rachael Sirianni was developing a treatment for medulloblastoma, an aggressive pediatric brain cancer. She had secured promising early results and applied for new NIH grants in late 2024.
But when administrative meetings to review her proposals were canceled after the change in administration, months of delays followed. With funding uncertain, Sirianni had to shrink her lab and suspend one of her most promising clinical trials.
Her experience reflects what many researchers nationwide are facing: stalled projects, shrinking labs, and doubts about the government’s commitment to supporting future cancer science. Experts warn that these disruptions could drive young scientists out of the field and slow innovation for years to come.
What’s at Stake
The United States is at a critical moment in cancer research. Advances in genetics, imaging, and treatment delivery are opening doors that scientists could not have imagined a generation ago. Yet sustained progress depends on stable funding and long-term support.
Without it, researchers caution that the country risks losing not only groundbreaking projects, but also an entire generation of scientific talent dedicated to fighting cancer.
READ MORE
Late Breakfasts in Diet Linked to Higher Death Risk in Later Life
